Estudios originales
Published on 21 de julio de 2025 | http://doi.org/10.5867/medwave.2025.06.3002
Thrombotic thrombocytopenic purpura: Description and analysis of 23 cases treated in Chile between 2017 and 2022
| Time from clinical presentation of TTP and its suspicion (days and IQR) | 5 (1 to 12) |
| In-hospital mortality (n and %) | 13 (56.5%) |
| Recurrence after hospital discharge (n and %) | 2 (20%) |
| Glucocorticoids (n and %) | 21 (91%) |
| Glucocorticoids + plasmapheresis (n and %) | 14 (61%) |
| Rituximab (n and %) | 9 (39%) |
| Other immunosuppressors or immunomodulators¹ | 7 (30%) |
| No treatment (n and %) | 2 (9%) |
| In-hospital infections (n and %) | 17 (74%) |
| Adverse events during plasmapheresis (n and %) | 14 (100%) |
| Minor (n and %) | 6 (43%) |
| Serious (n and %) | 8 (57%) |
IQR, interquartile range. TTP, thrombotic thrombocytopenic purpura. n, number.
¹Other immunosuppressants and immunomodulators include: 1 patient who used rituximab, cyclophosphamide and vincristine; 1patient rituximab and vincristine; 1 patient rituximab and mesalazine; 1 patient cyclophosphamide; 1 patient cyclosporine; 1 patient hydroxycarbamide; 1 patient mesalazine; 1 patient tacrolimus; 1 patient cyclophosphamide; 1 patient cyclosporine; 1 patient hydroxycarbamide; 1 patient mesalazine; 1 patient tacrolimus.
Source: Prepared by the authors of this study.